Recent Bioscience Sector press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —April 28, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.

1

 

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

1

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — February 3, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board (SAB).

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE - Mass. — January 27, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Dr. Cheryl Wellington to its scientific advisory board (SAB).

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 18, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses. Schizophrenia is a clinical term for a severely disabling neuropsychiatric disease that disrupts employment, families and communities, and likely has heterogenous biological origins.

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 7, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 AM PST.

1

 

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

1

 

[PRESSWIRE] Japan - 21 October, 2021 -- Post COVID-19 syndrome, a developing world-wide problem may be alleviated by Japan originated medical device "suisonia".

1

 

[PRESSWIRE] Vienna -- 17th August 2021 - CEBINA GmbH, Central European Biotech Incubator and Accelerator today announces the publication of the first results of a Phase 2 efficacy clinical trial sponsored jointly with its partner URSAPHARM Arzneimittel GmbH demonstrating that a nasal spray containing the active ingredient azelastine was effective in accelerating the reduction of the viral load in SARS-CoV-2 positive patients. Azelastine has been marketed in an identical composition by URSAPHARM for many years and is used as an antiallergic.

1

 

  • Carbon Engineering and BeZero Carbon join forces to offer a new retail option for customers seeking to address their carbon footprint through Direct Air Capture technology.
  • BeZero’s Carbon Rating Framework gives customers an additional tool to assess the quality of available solutions, with Direct Air Capture the only AAA+ top-rated solution.